{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:52:33Z","timestamp":1758959553380,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NCI","award":["UM1CA186690","U24CA247643","N01-CM-2011-00015C"],"award-info":[{"award-number":["UM1CA186690","U24CA247643","N01-CM-2011-00015C"]}]},{"DOI":"10.13039\/100006652","name":"National Center for Institutional Diversity, University of Michigan","doi-asserted-by":"publisher","award":["P30CA47904"],"award-info":[{"award-number":["P30CA47904"]}],"id":[{"id":"10.13039\/100006652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00280-023-04509-8","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:27:36Z","timestamp":1677133656000},"page":"219-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the indotecan\u2013neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Kennard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julianne L.","family":"Holleran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Zlott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivaani","family":"Kummar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wansu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jogarao","family":"Gobburu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"issue":"10","key":"4509_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6(10):789\u2013802. https:\/\/doi.org\/10.1038\/nrc1977","journal-title":"Nat Rev Cancer"},{"issue":"10018","key":"4509_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, Macarulla T, Lee K-H, Cunningham D, Blanc JF, Hubner RA, Chiu C-F, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen L-T, Adoo C, Anderson T, Asselah J, Azambuja A, Bampton C, Barrios CH, Bekaii-Saab T, Bohuslav M, Chang D, Chen J-S, Chen Y-C, Choi HJ, Chung IJ, Chung V, Csoszi T, Cubillo A, DeMarco L, de Wit M, Dragovich T, Edenfield W, Fein LE, Franke F, Fuchs M, Gonzales-Cruz V, Gozza A, Fernando RH, Iaffaioli R, Jakesova J, Kahan Z, Karimi M, Kim JS, Korbenfeld E, Lang I, Lee F-C, Lee K-D, Lipton L, Ma WW, Mangel L, Mena R, Palmer D, Pant S, Park JO, Piacentini P, Pelzer U, Plazas JG, Prasad C, Rau K-M, Raoul J-L, Richards D, Ross P, Schlittler L, Smakal M, Stahalova V, Sternberg C, Seufferlein T, Tebbutt N, Vinholes JJ, Wadlow R, Wenczl M, Wong M (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545\u2013557. https:\/\/doi.org\/10.1016\/s0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"4509_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13229-018-0228-2","volume":"9","author":"HM Lee","year":"2018","unstructured":"Lee HM, Clark EP, Kuijer MB, Cushman M, Pommier Y, Philpot BD (2018) Characterization and structure\u2013activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome. Mol Autism 9:45. https:\/\/doi.org\/10.1186\/s13229-018-0228-2","journal-title":"Mol Autism"},{"issue":"10","key":"4509_CR4","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1128\/AAC.00499-12","volume":"56","author":"R Balana-Fouce","year":"2012","unstructured":"Balana-Fouce R, Prada CF, Requena JM, Cushman M, Pommier Y, Alvarez-Velilla R, Escudero-Martinez JM, Calvo-Alvarez E, Perez-Pertejo Y, Reguera RM (2012) Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis. Antimicrob Agents Chemother 56(10):5264\u20135270. https:\/\/doi.org\/10.1128\/AAC.00499-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"4509_CR5","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1158\/1078-0432.CCR-18-1498","volume":"24","author":"JH Burton","year":"2018","unstructured":"Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y (2018) NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma. Clin Cancer Res 24(23):5830\u20135840. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1498","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4509_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00280-015-2722-y","volume":"75","author":"M Muzzio","year":"2015","unstructured":"Muzzio M, Hu SC, Holleran JL, Parise RA, Eiseman JL, Yellow-Duke AE, Covey JM, Glaze ER, Engelke K, Egorin MJ, McCormick DL, Beumer JH (2015) Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs. Cancer Chemother Pharmacol 75(5):1015\u20131023. https:\/\/doi.org\/10.1007\/s00280-015-2722-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4509_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00280-016-2998-6","volume":"78","author":"S Kummar","year":"2016","unstructured":"Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH (2016) Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemother Pharmacol 78(1):73\u201381. https:\/\/doi.org\/10.1007\/s00280-016-2998-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4509_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jpba.2010.02.020","volume":"52","author":"JL Holleran","year":"2010","unstructured":"Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH (2010) Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. J Pharm Biomed Anal 52(5):714\u2013720. https:\/\/doi.org\/10.1016\/j.jpba.2010.02.020","journal-title":"J Pharm Biomed Anal"},{"issue":"24","key":"4509_CR9","doi-asserted-by":"publisher","first-page":"10844","DOI":"10.1021\/jm300519w","volume":"55","author":"MA Cinelli","year":"2012","unstructured":"Cinelli MA, Reddy PV, Lv PC, Liang JH, Chen L, Agama K, Pommier Y, van Breemen RB, Cushman M (2012) Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons. J Med Chem 55(24):10844\u201310862. https:\/\/doi.org\/10.1021\/jm300519w","journal-title":"J Med Chem"},{"issue":"17","key":"4509_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317(17):1098. https:\/\/doi.org\/10.1056\/NEJM198710223171717","journal-title":"N Engl J Med"},{"issue":"1","key":"4509_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"issue":"2","key":"4509_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/b:jopa.0000034404.86036.72","volume":"31","author":"J Ribbing","year":"2004","unstructured":"Ribbing J, Jonsson EN (2004) Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 31(2):109\u2013134. https:\/\/doi.org\/10.1023\/b:jopa.0000034404.86036.72","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04509-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T11:04:52Z","timestamp":1679483092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4509"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04509-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"6 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.G. is a co-founder of Pumas AI, the company that developed the software, Pumas, which was used to develop this population PK model.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The data was generated in trials registered under ClinicalTrials.gov Identifiers NCT01051635 and NCT01794104. Informed consent Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}